Home / Central Data Catalog / FRESH-PEF74114-EN
central

Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice

France, 2013 - 2017
Reference ID
FRESH-PEF74114-en
Metadata
DDI/XML JSON
Study website Interactive tools
Created on
Feb 18, 2026
Last modified
Feb 18, 2026
Page views
49
  • Identification
  • Scope
  • Coverage
  • Producers and sponsors
  • Study authorization
  • Sampling
  • Survey instrument
  • Data collection
  • Quality standards
  • Data Access
  • Contacts

    • Identification

    Survey ID number

    FRESH-PEF74114-en
    Title

    Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice
    Abbreviation or Acronym

    AVANTAGE
    Country
    Name Country code
    France fr
    Kind of Data

    ['Clinical data']
    Unit of Analysis

    Individuals

    Scope

    Topics
    Topic Vocabulary
    Oncology health theme
    Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues cim-11
    Healthcare system determinants: Use of care health determinant
    Healthcare system determinants health determinant
    Keywords
    Bevacizumab

    Coverage

    Universe

    {"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Inclusion criteria : - Patient aged >= 65 years, - Diagnosed with advanced nsNSCLC (stage IIIB or IV), - For whom the physician has decided to initiate a treatment with bevacizumab combined with chemotherapy as 1st line therapy, - Having received oral and written information about the study, and having signed a written consent form.","clusion_E":""}

    Producers and sponsors

    Producers
    Name Role
    F. HOFFMANN-LA ROCHE AG sponsor

    Study authorization

    Agency
    Agency name
    Other

    Sampling

    Sample frame

    Unit Type

    ['Through organizations (health services or institutions, schools, businesses, etc.)']
    Sampling Procedure

    ['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']

    Survey instrument

    Questionnaires

    Access on specific project only
    Methodology notes

    Observational Study

    Data collection

    Dates of Data Collection
    Start End
    2013-01-01 2017-01-01
    Mode of data collection
    • {"concept":{"vocabURI":"Transcription","vocab":"CESSDA"},"value":"Converting or copying information into a structured record"}
    • {"concept":{"vocabURI":"Interview","vocab":"CESSDA"},"value":"Interview with the participant (including clinical)"}

    Quality standards

    Other quality statement

    ['GCP/GVP']

    Data Access

    Availability Status

    {"value":"Restricted access","extLink":[{"title":"COAR","uri":"http://purl.org/coar/access_right/c_16ec"}]}

    Contacts

    Contacts
    Name Email
    ;Medical data center data_sharing.france@roche.com
    Back to Catalog